Every AXLRx Cold Agglutinin Disease report, across 6 report types. Each is scoped to your asset and verified to a live source.
Sutimlimab (Enjaymo) is a ~$260K+/year Part B IV biologic in a few-thousand-patient population — and not cost-effective at the current price.
Sutimlimab (Enjaymo) is the only FDA-approved CAD therapy — competing against off-label rituximab-based standard of care, not a branded rival.
A rare classical-complement autoimmune hemolytic anemia driven by cold-reactive IgM — primary CAD vs cold agglutinin syndrome, and the US hemolysis burden.
Sutimlimab's CARDINAL trial left 46% of patients without a hemoglobin response, yet the two most-advanced next-generation complement inhibitors abandoned cold agglutinin disease after its launch, leaving the entry gap defined by non-response and cost, not a clinical rival.
Sutimlimab costs $259,000-$302,000 per patient per year, and a peer-reviewed analysis puts its ICER at $2.34M/QALY, standard of care favored in all 10,000 probabilistic-sensitivity iterations. The value gap, not a rival drug, sets the pricing discipline.
US cold agglutinin disease sizing starts from a rate range, not a point estimate: incidence 0.6-1.2 and 1-year prevalence 1.4-3.1 per 100,000, implying ~5,000 prevalent patients. No published treated-share figure exists to split served from total addressable.
AXLRx publishes Payer & HTA, Competitive Intelligence, Disease Landscape, Launch Readiness, Pricing Strategy Model, and Market Sizing Model for Cold Agglutinin Disease. Each report is scoped to your asset, verified to a live source, and delivered in 72 hours.
Current Cold Agglutinin Disease coverage spans United States. Additional markets can be commissioned against the same evidence standard.
Every figure is cited to a live source at the point of writing and re-checked in an independent audit pass. The latest Cold Agglutinin Disease reports were updated July 2026.